Drug Trial Radar · NCT07679282
A Comparative Effectiveness Study of Positive Airway Pressure (PAP) Therapy, Dental Device, and Atomoxetine-Oxybutynin for Treatment of Obstructive Sleep Apnea in Adults
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,400
Planned (sponsor's estimate)
Start
Sep 4, 2026
Primary completion
Mar 1, 2030
Study completion May 1, 2032
Sponsor
- Lead sponsor
- Sairam ParthasarathyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Patient-Centered Outcomes Research Institute; University of Arizona; University of Maryland; University of Miami; Stanford University
- First posted
- Jul 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers want to identify which treatments for obstructive sleep apnea (OSA) work best and are easiest for patients to use consistently. Eligible participants will be randomly assigned one of three OSA treatments: traditional PAP therapy, a dental device, or a combination of two FDA-approved medications (atomoxetine and oxybutynin) that are currently approved for other conditions. Over the course of one year, participants will attend two in-person visits and take part in four phone check-ins to complete surveys, report any side effects, and discuss how well they are following their assigned treatment.
Conditions
- Obstructive Sleep Apnea (OSA)
Interventions
Positive airway pressure (PAP) therapyDevice
Positive airway pressure delivered via a nasal or face mask while a patient sleeps to keep the airways open.
Sleep dental deviceDevice
An oral appliance worn during sleep to move the lower jaw forward, which tightens soft tissues and widens the airway to prevent sleep apnea.
Atomoxetine-oxybutyninDrug
The combination of two medications (atomoxetine-oxybutynin) can reduce obstructive sleep apnea by increasing upper airway muscle activity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Health-related quality of lifeTime frame: At 12 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Banner University Medical Center Tucson
Tucson, Arizona · Recruiting
Stanford Medical Center
Redwood City, California · Recruiting
University of Miami Miller School of Medicine
Miami, Florida · Not yet recruiting
University of Maryland Baltimore
Baltimore, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.